| Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry A Sundlöv, K Sjögreen-Gleisner, J Svensson, M Ljungberg, T Olsson, ... European journal of nuclear medicine and molecular imaging 44, 1480-1489, 2017 | 211 | 2017 |
| The role of RANK‐ligand inhibition in cancer: the story of denosumab D Castellano, JM Sepulveda, I García‐Escobar, A Rodriguez‐Antolín, ... The oncologist 16 (2), 136-145, 2011 | 159 | 2011 |
| Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms ET Janson, H Sorbye, S Welin, B Federspiel, H Grønbæk, P Hellman, ... Acta Oncologica 53 (10), 1284-1297, 2014 | 145 | 2014 |
| The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms A Venizelos, H Elvebakken, A Perren, O Nikolaienko, W Deng, IMB Lothe, ... Endocrine-related cancer 29 (1), 1-14, 2022 | 109 | 2022 |
| Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy A Sundlöv, J Gustafsson, G Brolin, N Mortensen, R Hermann, P Bernhardt, ... EJNMMI physics 5, 1-19, 2018 | 80 | 2018 |
| Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal … L Hagmarker, J Svensson, T Rydén, M van Essen, A Sundlöv, ... Journal of Nuclear Medicine 60 (10), 1406-1413, 2019 | 70 | 2019 |
| Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients A Sundlöv, KS Gleisner, J Tennvall, M Ljungberg, CF Warfvinge, ... European journal of nuclear medicine and molecular imaging 49 (11), 3830-3840, 2022 | 68 | 2022 |
| Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE D Roth, J Gustafsson, CF Warfvinge, A Sundlöv, A Åkesson, J Tennvall, ... Journal of Nuclear Medicine 63 (3), 399-405, 2022 | 50 | 2022 |
| Long-term retention of 177Lu/177mLu-DOTATATE in patients investigated by γ-spectrometry and γ-camera imaging KS Gleisner, G Brolin, A Sundlöv, E Mjekiqi, K Östlund, J Tennvall, ... Journal of Nuclear Medicine 56 (7), 976-984, 2015 | 50 | 2015 |
| SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy J Gustafsson, A Sundlöv, K Sjögreen Gleisner EJNMMI research 7, 1-17, 2017 | 49 | 2017 |
| A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors A Gålne, H Almquist, M Almquist, C Hindorf, T Ohlsson, E Nordenström, ... Journal of Nuclear Medicine 60 (12), 1717-1723, 2019 | 39 | 2019 |
| Surgery of the primary tumour in 201 patients with high‐grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine‐non‐neuroendocrine neoplasms HC Pommergaard, K Nielsen, H Sorbye, B Federspiel, EM Tabaksblat, ... Journal of neuroendocrinology 33 (5), e12967, 2021 | 37 | 2021 |
| A method for tumor dosimetry based on hybrid planar‐SPECT/CT images and semiautomatic segmentation D Roth, J Gustafsson, A Sundlöv, K Sjögreen Gleisner Medical physics 45 (11), 5004-5018, 2018 | 28 | 2018 |
| Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy A Stenvall, J Gustafsson, E Larsson, D Roth, A Sundlöv, L Jönsson, ... EJNMMI research 12 (1), 75, 2022 | 23 | 2022 |
| Quantitative analysis of phantom studies of 111In and 68Ga imaging of neuroendocrine tumours L Jönsson, A Stenvall, E Mattsson, E Larsson, A Sundlöv, T Ohlsson, ... EJNMMI physics 5, 1-13, 2018 | 22 | 2018 |
| Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up A Sundlöv, K Sjögreen-Gleisner, J Tennvall, L Dahl, J Svensson, ... Neuroendocrinology 111 (4), 344-353, 2021 | 18 | 2021 |
| Peptide receptor radionuclide therapy–prospects for personalised treatment A Sundlöv, K Sjögreen-Gleisner Clinical Oncology 33 (2), 92-97, 2021 | 16 | 2021 |
| Health-Related quality of life after surgery for small intestinal neuroendocrine tumours AC Milanetto, E Nordenström, A Sundlöv, M Almquist World Journal of Surgery 42, 3231-3239, 2018 | 16 | 2018 |
| The effect of radioiodine treatment on TRAb, anti-TPO, and anti-TG in Graves’ disease O Lindgren, P Asp, A Sundlöv, J Tennvall, B Shahida, T Planck, P Åsman, ... European Thyroid Journal 8 (2), 64-69, 2019 | 15 | 2019 |
| Mutation spectrum in liquid versus solid biopsies from patients with advanced gastroenteropancreatic neuroendocrine carcinoma S Knappskog, T Grob, A Venizelos, U Amstutz, GO Hjortland, IM Lothe, ... JCO precision oncology 7, e2200336, 2023 | 13 | 2023 |
